Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 357

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 357
---
; (ii) failure
to declare or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S-1
or Form S-3 pursuant to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion
failure or notice of the Company’s intention not to comply with a request for conversion of any Series D Preferred Stock, and
(iv) bankruptcy or insolvency of the Company.

Other Adjustments.
In connection with the April 2025 Private Placement, the Company has agreed to seek stockholder approval at a special meeting of
stockholders, of the issuance of Conversion Shares at a conversion price below the Conversion Price (the date of such approval, the “Series D
Stockholder Approval Date”). If the Company did not obtain such stockholder approval prior to May 31, 2025, then the Company
would have been required to (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC no later than May 31,
2025, (ii) use reasonable best efforts to file the definitive Proxy Statement no later than June 30, 2025 and (iii) use
reasonable best efforts to hold the Stockholder Meeting no later than July 31, 2025. Such stockholder approval was obtained on May
29, 2025. If, on or after the Series D Stockholder Approval Date, the Company issues any shares of Common Stock for a consideration
per share (the “Series D New Issuance Price”) less than a price equal to the Series D Conversion Price in effect
immediately prior to such issuance, the Conversion Price shall be reduced to the Series D New Issuance Price.

F-20 If 30 days or 60 days following the occurrence of the later of (x) the Series D Stockholder Approval Date and (y) the earlier of (a) the effective date of the registration statement to be filed pursuant to the Registration Rights Agreement and (b) the date that the Series D Preferred Stock is eligible to be resold without restriction under Rule 144 of the Securities Act, the Series D Conversion Price then in effect is the greater of $ 3.12and the Market Price (as defined in the Series D Certificate of Designations) then in effect (the “Series D Adjustment Price”), the Conversion Price shall automatically lower to the Series D Adjustment Price. On August 13, 2025, the Company and the Investors of Series